Synthesis and Structure–Activity Relationship of Dehydrodieugenol B Neolignans against <i>Trypanosoma cruzi</i>
Claire E. Sear, Pauline Pieper, Maiara Amaral, Maiara M. Romanelli, Thais A. Costa‐Silva, Marius M. Haugland, Joseph A. Tate, João Henrique G. Lago, André G. Tempone, Edward A. Anderson
Abstract
) of >200 μM). Five of these analogues meet the Drugs for Neglected Disease Initiative (DNDi) "hit criteria" for Chagas disease. This work has enabled the identification of key structural features of the natural product and sites where scaffold modification is tolerated.
Topics & Concepts
Trypanosoma cruziChagas diseaseNatural productAmastigoteAntiparasiticBiologyPharmacologyStructure–activity relationshipAntiparasitic agentIn vitroBiochemistryVirologyMedicineParasite hostingLeishmaniaPathologyComputer scienceWorld Wide WebPlant-derived Lignans Synthesis and BioactivityPhytochemical compounds biological activitiesTraditional and Medicinal Uses of Annonaceae